Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safflower extract and aceglutamide for prevention of chemobrain
ChiCTR-IIR-16009298Phase 2Recruiting
- Sponsor
- Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
- Start
- Sep 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Guhong Injection in breast cancer, non-small cell lung cancer (NSCLC), ovarian cancer and 1 more (2 arms), sponsored by Central Hospital of Enshi Tujia and Miao Autonomous Prefecture. Primary endpoints: cognitive status and brain connectivity. Started Sep 2016; status: recruiting.
02
Drugs
Guhong Injection
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)ovarian cancerpostchemotherapy cognitive impairment (CRCI)
Beyond the preview
Go deeper on ChiCTR-IIR-16009298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16009298.